MX2011011130A - Proteina o peptido de fusion con vida media in vivo incrementada mantenido por liberacion in vivo sostenida, y metodo para incrementar la vida media in vivo usando el mismo. - Google Patents
Proteina o peptido de fusion con vida media in vivo incrementada mantenido por liberacion in vivo sostenida, y metodo para incrementar la vida media in vivo usando el mismo.Info
- Publication number
- MX2011011130A MX2011011130A MX2011011130A MX2011011130A MX2011011130A MX 2011011130 A MX2011011130 A MX 2011011130A MX 2011011130 A MX2011011130 A MX 2011011130A MX 2011011130 A MX2011011130 A MX 2011011130A MX 2011011130 A MX2011011130 A MX 2011011130A
- Authority
- MX
- Mexico
- Prior art keywords
- vivo
- life
- peptide
- vivo half
- fusion protein
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
- C07K14/8121—Serpins
- C07K14/8125—Alpha-1-antitrypsin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente invención se refiere a una proteína o péptido de fusión, cuya vida media in vivo se incrementa porque mantiene liberación sostenida in vivo, y a un método para incrementar la vida media in vivo usando el mismo; una proteína o péptido de fusión de conformidad con la presente invención, tiene excelente estabilidad in vivo por la unión de una proteína fisiológicamente activa o un péptido fisiológicamente activo a una antitripsina alfa-1 o mutante de antitripsina alfa-1 con uno o más aminoácidos mutados que mantiene liberación sostenida in vivo e incrementa significativamente la vida media del mismo en la sangre (T1/2), en comparación con una proteína fisiológicamente activa o un péptido fisiológicamente activo inherente; de esta manera, una proteína o péptido de fusión de conformidad con la presente invención puede ser útil en el desarrollo de una preparación de liberación sostenida de un fármaco de proteínas o péptidos.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20090035190 | 2009-04-22 | ||
| PCT/KR2010/002520 WO2010123290A2 (ko) | 2009-04-22 | 2010-04-22 | 체내 지속성을 유지함으로 체내 반감기가 증가된 단백질 또는 펩티드 융합체, 및 이를 이용하여 체내 반감기를 증가시키는 방법 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2011011130A true MX2011011130A (es) | 2011-11-18 |
Family
ID=43011621
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2011011130A MX2011011130A (es) | 2009-04-22 | 2010-04-22 | Proteina o peptido de fusion con vida media in vivo incrementada mantenido por liberacion in vivo sostenida, y metodo para incrementar la vida media in vivo usando el mismo. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US9012606B2 (es) |
| EP (1) | EP2423233B1 (es) |
| JP (1) | JP5727459B2 (es) |
| KR (1) | KR101183262B1 (es) |
| CN (1) | CN102439044B (es) |
| AU (1) | AU2010239861B2 (es) |
| BR (1) | BRPI1006443B1 (es) |
| CA (1) | CA2758445C (es) |
| MX (1) | MX2011011130A (es) |
| RU (1) | RU2503688C2 (es) |
| WO (1) | WO2010123290A2 (es) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2723370A4 (en) | 2011-06-24 | 2015-06-03 | Univ Colorado Regents | COMPOSITIONS, PROCESS AND USE OF ALPHA-1-ANTITRYPHIN FUSION MOLECULES |
| US10400029B2 (en) | 2011-06-28 | 2019-09-03 | Inhibrx, Lp | Serpin fusion polypeptides and methods of use thereof |
| KR20210032558A (ko) | 2011-06-28 | 2021-03-24 | 인히브릭스, 인크. | 세르핀 융합 폴리펩타이드 및 이의 이용 방법 |
| KR101402702B1 (ko) * | 2011-09-15 | 2014-06-05 | (주)알테오젠 | 신규한 알파-1 안티트립신 변이체, 이의 제조방법 및 용도 |
| EP2802653A4 (en) | 2012-01-10 | 2015-09-02 | Univ Colorado Regents | ALPHA-1 ANTITRYPSIN FUSION MOLECULE COMPOSITIONS, METHODS AND USES THEREOF |
| KR102238317B1 (ko) | 2012-05-17 | 2021-04-12 | 익스텐드 바이오사이언시즈, 인크. | 개선된 약물 전달용 캐리어 |
| KR101460266B1 (ko) * | 2012-06-05 | 2014-11-11 | 씨제이헬스케어 주식회사 | 신규한 지속형 인간 성장호르몬의 정제 방법 |
| EP2857417B1 (en) * | 2012-06-05 | 2018-02-14 | CJ Healthcare Corporation | Highly glycosylated long-acting human growth hormone protein and production method for same |
| KR101504824B1 (ko) * | 2013-05-31 | 2015-03-23 | 씨제이헬스케어 주식회사 | 고당화된 지속형 인간 성장호르몬 단백질 및 이의 제조방법 |
| UA116217C2 (uk) | 2012-10-09 | 2018-02-26 | Санофі | Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону |
| KR101516054B1 (ko) * | 2012-11-21 | 2015-05-06 | 씨제이헬스케어 주식회사 | 신규한 지속형 인간 성장호르몬 단량체를 제조하는 방법 |
| EP2934569A1 (en) | 2012-12-21 | 2015-10-28 | Sanofi | Exendin-4 derivatives |
| TW201609795A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 作為雙重ｇｌｐ－１／ｇｉｐ受體促效劑的艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物 |
| GB201322091D0 (en) | 2013-12-13 | 2014-01-29 | Cambridge Entpr Ltd | Modified serpins for the treatment of bleeding disorders |
| WO2015086733A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Dual glp-1/glucagon receptor agonists |
| EP3080152A1 (en) | 2013-12-13 | 2016-10-19 | Sanofi | Non-acylated exendin-4 peptide analogues |
| TW201609799A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 雙重ｇｌｐ－１／ｇｉｐ受體促效劑 |
| TW201625668A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物 |
| TW201625669A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑 |
| TW201625670A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑 |
| US9932381B2 (en) | 2014-06-18 | 2018-04-03 | Sanofi | Exendin-4 derivatives as selective glucagon receptor agonists |
| JP6946182B2 (ja) | 2014-10-22 | 2021-10-06 | エクステンド バイオサイエンシズ インコーポレーテッドＥｘｔｅｎｄ Ｂｉｏｓｃｉｅｎｃｅｓ， Ｉｎｃ | 治療用ビタミンｄコンジュゲート |
| WO2016065052A1 (en) | 2014-10-22 | 2016-04-28 | Extend Biosciences, Inc. | Insulin vitamin d conjugates |
| US9789197B2 (en) | 2014-10-22 | 2017-10-17 | Extend Biosciences, Inc. | RNAi vitamin D conjugates |
| JP2018502908A (ja) * | 2014-12-22 | 2018-02-01 | ノヴォ ノルディスク アー／エス | アルファ‐１‐ アンチトリプシン（ａ１ａｔ）融合タンパク質及びその使用 |
| CN106390100B (zh) * | 2015-01-28 | 2021-06-22 | 中国科学院天津工业生物技术研究所 | 一种多肽复合物作为glp-1药物载体的应用、方法及其融合蛋白复合物 |
| US10993993B2 (en) * | 2015-05-28 | 2021-05-04 | Immunoforge Co., Ltd. | Pharmaceutical composition for treating muscle atrophy or sarcopenia including glucagon-like peptide (GLP-1) or GLP-1 receptor agonist |
| AR105319A1 (es) | 2015-06-05 | 2017-09-27 | Sanofi Sa | Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico |
| KR20170004814A (ko) | 2015-07-02 | 2017-01-11 | 주식회사 녹십자 | 헌터증후군 치료제 |
| WO2017003270A1 (ko) * | 2015-07-02 | 2017-01-05 | 주식회사 녹십자 | 헌터증후군 치료제 및 치료방법 |
| TW201706291A (zh) | 2015-07-10 | 2017-02-16 | 賽諾菲公司 | 作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物 |
| AU2016319540B2 (en) * | 2015-09-08 | 2021-08-26 | Jcr Pharmaceuticals Co., Ltd. | Novel human serum albumin mutant |
| WO2018071528A1 (en) * | 2016-10-11 | 2018-04-19 | University Of Georgia Research Foundation, Inc. | Proteins and method for treating obesity and associated comorbidities |
| WO2018185756A1 (en) * | 2017-04-02 | 2018-10-11 | B. G. Negev Technologies And Applications Ltd., At Ben-Gurion University | Mutant alpha-1-antitrypsin compositions and use thereof |
| KR101964376B1 (ko) | 2017-09-29 | 2019-04-01 | 주식회사 나이벡 | 부갑상선호르몬(parathyroid hormone, PTH)에 골조직 선택성 펩타이드가 결합되어 있는 융합 펩타이드를 포함하는 약학 조성물 및 생체재료 |
| KR102167827B1 (ko) * | 2017-12-20 | 2020-10-20 | 주식회사 알테오젠 | 신규한 성장 호르몬 수용체 길항제 및 이의 융합 단백질 |
| CN107916257B (zh) * | 2018-01-09 | 2020-07-28 | 华南理工大学 | T1脂肪酶突变体和应用 |
| US20190351031A1 (en) | 2018-05-16 | 2019-11-21 | Halozyme, Inc. | Methods of selecting subjects for combination cancer therapy with a polymer-conjugated soluble ph20 |
| WO2019237079A2 (en) * | 2018-06-07 | 2019-12-12 | Xiaolong Zhang | Pharmaceutical composition containing fusion protein and use thereof |
| KR102263105B1 (ko) * | 2018-09-05 | 2021-06-09 | 주식회사 엘지화학 | O-글리코실화 가능한 폴리펩타이드 영역을 포함하는 융합 폴리펩타이드 |
| CN114573715A (zh) * | 2022-03-14 | 2022-06-03 | 江苏雅酶医药科技有限公司 | 一种重组长效人透明质酸酶及其生产方法和应用 |
| CN117186237A (zh) * | 2022-05-29 | 2023-12-08 | 中国医学科学院药物研究所 | 一种含有糜蛋白酶抑制肽的胰岛素杂交肽及其应用 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2601033B1 (fr) * | 1986-07-02 | 1990-01-19 | Transgene Sa | Variants de l'alpha-antitryspine humaine glycosylee et procede pour la preparation |
| US5116964A (en) | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
| US5605690A (en) | 1989-09-05 | 1997-02-25 | Immunex Corporation | Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor |
| US7217689B1 (en) | 1989-10-13 | 2007-05-15 | Amgen Inc. | Glycosylation analogs of erythropoietin |
| FR2686899B1 (fr) | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
| FR2686901A1 (fr) | 1992-01-31 | 1993-08-06 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides antithrombotiques, leur preparation et compositions pharmaceutiques les contenant. |
| KR100239336B1 (ko) | 1992-09-29 | 2000-01-15 | 구본준 | 액정 표시 소자 |
| WO1994012158A1 (en) | 1992-12-02 | 1994-06-09 | Alkermes Controlled Therapeutics, Inc. | Controlled release growth hormone containing microspheres |
| KR100236771B1 (ko) | 1997-04-01 | 2000-02-01 | 성재갑 | 히아루론산을 이용한 약물의 서방성 미세입자 제형 |
| US7247704B2 (en) * | 2000-12-18 | 2007-07-24 | Arriva Pharmaceuticals, Inc. | Multifunctional protease inhibitors and their use in treatment of disease |
| US20080095774A1 (en) * | 2001-02-16 | 2008-04-24 | Wyeth | Agents and Methods for Specifically Blocking CD28-Mediated Signaling |
| US7176278B2 (en) | 2001-08-30 | 2007-02-13 | Biorexis Technology, Inc. | Modified transferrin fusion proteins |
| CA2534352A1 (en) * | 2003-08-08 | 2005-02-17 | Arriva Pharmaceuticals, Inc. | Methods of protein production in yeast |
| KR100775343B1 (ko) | 2003-11-13 | 2007-11-08 | 한미약품 주식회사 | 면역글로불린 Ｆｃ 영역을 캐리어로 포함하는 약제학적조성물 |
| KR20120133403A (ko) * | 2004-06-01 | 2012-12-10 | 도만티스 리미티드 | 증강된 혈청 반감기를 가지는 이특이성 융합 항체 |
| US8658174B2 (en) | 2005-07-27 | 2014-02-25 | Qinghua Wang | GLP/1/exendin 4 IgG Fc fusion constructs for treatment of diabetes |
-
2010
- 2010-04-22 KR KR1020100037496A patent/KR101183262B1/ko active IP Right Grant
- 2010-04-22 EP EP10767304.8A patent/EP2423233B1/en active Active
- 2010-04-22 RU RU2011147216/10A patent/RU2503688C2/ru active
- 2010-04-22 BR BRPI1006443-5A patent/BRPI1006443B1/pt active IP Right Grant
- 2010-04-22 AU AU2010239861A patent/AU2010239861B2/en active Active
- 2010-04-22 CA CA2758445A patent/CA2758445C/en active Active
- 2010-04-22 JP JP2012505833A patent/JP5727459B2/ja active Active
- 2010-04-22 CN CN201080017980.6A patent/CN102439044B/zh active Active
- 2010-04-22 MX MX2011011130A patent/MX2011011130A/es active IP Right Grant
- 2010-04-22 US US13/265,775 patent/US9012606B2/en active Active
- 2010-04-22 WO PCT/KR2010/002520 patent/WO2010123290A2/ko active Application Filing
Also Published As
| Publication number | Publication date |
|---|---|
| CN102439044B (zh) | 2014-08-13 |
| BRPI1006443B1 (pt) | 2021-05-25 |
| CA2758445A1 (en) | 2010-10-28 |
| CA2758445C (en) | 2016-02-16 |
| US9012606B2 (en) | 2015-04-21 |
| AU2010239861B2 (en) | 2013-07-11 |
| JP5727459B2 (ja) | 2015-06-03 |
| RU2011147216A (ru) | 2013-05-27 |
| EP2423233B1 (en) | 2015-03-11 |
| US20120094356A1 (en) | 2012-04-19 |
| AU2010239861A1 (en) | 2011-10-27 |
| KR20100116558A (ko) | 2010-11-01 |
| CN102439044A (zh) | 2012-05-02 |
| WO2010123290A2 (ko) | 2010-10-28 |
| JP2012524062A (ja) | 2012-10-11 |
| EP2423233A4 (en) | 2012-09-26 |
| BRPI1006443A2 (pt) | 2016-09-27 |
| RU2503688C2 (ru) | 2014-01-10 |
| WO2010123290A3 (ko) | 2011-03-03 |
| EP2423233A2 (en) | 2012-02-29 |
| KR101183262B1 (ko) | 2012-09-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2011011130A (es) | Proteina o peptido de fusion con vida media in vivo incrementada mantenido por liberacion in vivo sostenida, y metodo para incrementar la vida media in vivo usando el mismo. | |
| MY151184A (en) | A polypeptide complex comprising non-peptidyl polymer having three functional ends | |
| MX2009004147A (es) | Vacunas de peptido para canceres que expresan polipeptidos mphosph1 o depdc1. | |
| SG178797A1 (en) | Oligosaccharide chain added glp-1 peptide | |
| NZ624533A (en) | Novel immunotherapy against several tumors including neuronal and brain tumors | |
| NZ590050A (en) | Fgf21 mutants and uses thereof | |
| RS54215B1 (en) | COMPOSITIONS AND PROCEDURES FOR DIAGNOSIS AND TREATMENT OF CANCER | |
| PE20090711A1 (es) | Region constante de anticuerpo mutante | |
| SG196821A1 (en) | New stable formulations of recombinant human albumin-human granulocyte colony stimulating factor fusion protein | |
| ATE457310T1 (de) | Amid substituierte 8-n-benzimidazole, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel | |
| DK1180121T3 (da) | Langtidsvirkende insulinotrope peptider | |
| MX2008004734A (es) | Composicion rica en leucina. | |
| CA2766039A1 (en) | Arginase formulations and methods | |
| UA95235C2 (en) | Glucagon-like-peptide-2 (glp-2) analogues | |
| EP2573110A3 (en) | Peptide vaccines with Seq Id No: 174, 178, 186 or 194 for cancers expressing tumor-associated antigens | |
| EA200802170A1 (ru) | Лиофилизированная композиция терапевтического пептидного антитела | |
| TW200716751A (en) | A variant form of urate oxidase and use thereof | |
| MX2012007416A (es) | Composiciones y metodos para el tratamiento de enfermedades oculares relacionadas con la angiogenesis. | |
| CA2504377A1 (en) | Pharmaceutical preparation of recombinant factor viii lyophilized without albumin as a stabilizer | |
| NZ596658A (en) | Dig-10 insecticidal cry toxins | |
| NZ601592A (en) | Recombinant elastase proteins and methods of manufacturing and use thereof | |
| NZ562436A (en) | Toll-like receptor 14 (TLR14) and use thereof | |
| SG162744A1 (en) | Stable active ingredient complex of salts of the o-acetylsalicylic acid with basic amino acids and glycine | |
| WO2009064366A3 (en) | Methods and compositions for protein labeling using lipoic acid ligases | |
| UA100127C2 (ru) | Пептид cdh3 и лекарственное средство, содержащее его |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |